243 related articles for article (PubMed ID: 29805739)
21. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
22. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
23. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
24. Classification of gallbladder cancer by assessment of CD8
Lin J; Long J; Wan X; Chen J; Bai Y; Wang A; Yang X; Wu Y; Robson SC; Sang X; Zhao H
BMC Cancer; 2018 Jul; 18(1):766. PubMed ID: 30055582
[TBL] [Abstract][Full Text] [Related]
25. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma.
Ueno T; Tsuchikawa T; Hatanaka KC; Hatanaka Y; Mitsuhashi T; Nakanishi Y; Noji T; Nakamura T; Okamura K; Matsuno Y; Hirano S
Oncotarget; 2018 Apr; 9(28):20034-20047. PubMed ID: 29732001
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
29. High tumoral PD-L1 expression and low PD-1
Kim S; Nam SJ; Park C; Kwon D; Yim J; Song SG; Ock CY; Kim YA; Park SH; Kim TM; Jeon YK
Oncoimmunology; 2019; 8(9):e1626653. PubMed ID: 31428525
[TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
[TBL] [Abstract][Full Text] [Related]
31. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
32. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
33. Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.
Lan C; Kitano Y; Yamashita YI; Yamao T; Kajiyama K; Yoshizumi T; Fukuzawa K; Sugimachi K; Ikeda Y; Takamori H; Miyanari N; Hirota M; Baba H
Br J Cancer; 2022 Feb; 126(2):219-227. PubMed ID: 34616011
[TBL] [Abstract][Full Text] [Related]
34. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
35. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
Ohtaki Y; Kaira K; Atsumi J; Nagashima T; Kawashima O; Ibe T; Kamiyoshihara M; Onozato R; Fujita A; Yazawa T; Sugano M; Iijima M; Nakazawa S; Obayashi K; Kosaka T; Yajima T; Kuwano H; Shirabe K; Mogi A; Shimizu K
Am J Transl Res; 2018; 10(10):3243-3253. PubMed ID: 30416665
[TBL] [Abstract][Full Text] [Related]
37. Characterization of PD-L1 protein expression and CD8
Sun Y; Zhai C; Chen X; Dong Z; Hou L; Zhou C; Jiang T
Transl Lung Cancer Res; 2019 Dec; 8(6):748-759. PubMed ID: 32010554
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
39. Distribution characteristics and prognosis of tumor-infiltrating lymphocytes in the brain metastases of small cell lung cancer: a retrospective cohort study.
Qian H; Pang J; Wan C; Mei X; Liao J; Wang B; Milano MT; Suwinski R; Inno A; Du Y
Transl Cancer Res; 2024 May; 13(5):2509-2517. PubMed ID: 38881925
[TBL] [Abstract][Full Text] [Related]
40. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
